Brazilian Ibd Study Group Position Statement on Sars-Cov2 Vaccination

Queiroz, Natália Sousa Freitas; Teixeira, Fábio Vieira; Freire, Caio Castro; Motta, Marina Pamponet; Vasconcellos, Marcela Almeida Menezes de; Chebli, Liliana Andrade; Saad-Hossne, Rogério

doi:10.1590/s0004-2803.202100000-02

Cited by 6 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 Similarly, a Brazilian IBD study group proposed that the SARS-CoV-2 vaccination can be administrated irrespective of the timing and dosage of the last biologic agent received, but vaccination should be avoided on the day of biologic agent administration to allow www.irjournal.org the cause of any adverse effects to be distinguished. 44 Therefore, IBD patients being treated with biological agents can be vaccinated regardless of the timing of drug administration. However, if possible, administering the SARS-CoV-2 vaccine on a different day than the administration of the biological agent will help to check for side effects.…”

Section: Statementmentioning

confidence: 99%

“…The IOIBD also recommends the early vaccination of IBD patients regardless of the timing of biologic treatment [ 17 ]. Similarly, a Brazilian IBD study group proposed that the SARS-CoV-2 vaccination can be administrated irrespective of the timing and dosage of the last biologic agent received, but vaccination should be avoided on the day of biologic agent administration to allow the cause of any adverse effects to be distinguished [ 44 ]. Therefore, IBD patients being treated with biological agents can be vaccinated regardless of the timing of drug administration.…”

Section: General Issues and Safetymentioning

confidence: 99%

See 1 more Smart Citation

SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID

et al. 2022

View full text Add to dashboard Cite

Coronavirus disease 2019 , caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy.

show abstract

Section: Statementmentioning

confidence: 99%

Section: General Issues and Safetymentioning

confidence: 99%

SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Despite these concerns, vaccine effectiveness seems to be the key concern, rather than safety. All the entities and experts recommend COVID‐19 vaccination for IBD patients, 151 , 152 , 153 , 154 , 155 including those who had anaphylaxis following biologic treatment. 151 …”

Section: Covid‐19 Vaccines: Where Are We Now?mentioning

confidence: 99%

“…Despite these concerns, vaccine effectiveness seems to be the key concern, rather than safety. All the entities and experts recommend COVID-19 vaccination for IBD patients, [151][152][153][154][155] including those who had anaphylaxis following biologic treatment. 151 In addition, the British Society of Gastroenterology and the British Association for the Study of the Liver recommend that patients with CLD, AIH, and those with liver transplants shall be vaccinated for COVID-19, with one of the available vacines.…”

Section: Covid-19 and Endoscopymentioning

confidence: 99%

COVID‐19 in gastroenterology: Where are we now? Current evidence on the impact of COVID‐19 in gastroenterology

et al. 2021

View full text Add to dashboard Cite

Background The COVID‐19 pandemic has created unprecedented challenges in all fields of society with social, economic, and health‐related consequences worldwide. In this context, gastroenterology patients and healthcare systems and professionals have seen their routines changed and were forced to adapt, adopting measures to minimize the risk of infection while guaranteeing continuous medical care to chronic patients. Objective At this point, it is important to evaluate the impact of the pandemic on this field to further improve the quality of the services provided in this context. Methods/Results/Conclusion We performed a literature review that summarizes the main aspects to consider in gastroenterology, during the pandemic crisis, and includes a deep discussion on the main changes affecting gastroenterology patients and healthcare systems, anticipating the pandemic recovery scenario with future practices and policies.

show abstract

“…All available vaccines are considered equally safe and effective for IBD patients; however, vaccine efficacy may be decreased in those receiving systemic corticosteroids. As far as patients under biological treatment are concerned, the only recommendation is to avoid receiving the vaccine on the same day as an infusion/subcutaneous dose, to avoid misinterpretation in case an adverse event occurs [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 pandemic on the healthcare and psychosocial well-being of patients with inflammatory bowel disease

Theodorou-Kanakari¹

2022

aog

View full text Add to dashboard Cite

COVID-19 pandemic has resulted in unprecedented disruptions to several aspects of gastroenterology healthcare services worldwide. In particular, patients with inflammatory bowel disease (IBD) represent a sensitive population that must retain access to healthcare services to avoid potential disease exacerbation under the continuous threat of viral infection. Emerging evidence also highlights the severe impact on these patients’ mental well-being, leading to a constant cycle of stress/depression and disease activity relapse. In an effort to circumvent these healthcare challenges in a newly-shaped environment, physicians implemented telemedicine consultative care programs as a novel alternative follow-up method highly favored by the patients. The situation is still far from perfect, since a large proportion of patients are lost to follow up and/or lose adherence to their medication, especially when the exact timeframe or optimal strategy for the post-COVID era remains to be defined. Cancelation of elective endoscopic procedures has led to a significant decline of new IBD diagnoses. This review summarizes the data on the global impact of COVID-19 on IBD patients’ healthcare and their psychosocial status.

show abstract

Brazilian Ibd Study Group Position Statement on Sars-Cov2 Vaccination

Cited by 6 publications

References 8 publications

SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID

SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID

COVID‐19 in gastroenterology: Where are we now? Current evidence on the impact of COVID‐19 in gastroenterology

Impact of COVID-19 pandemic on the healthcare and psychosocial well-being of patients with inflammatory bowel disease

Contact Info

Product

Resources

About